DARVOCET A500 bulk active fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
RR Scientific	⤷ Get Started Free	R6413122	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: November 19, 2025

Introduction

DARVOCET A500, a combination drug historically utilized for mild to moderate pain relief, contains two active pharmaceutical ingredients (APIs): acetaminophen and propoxyphene napsylate. Although propoxyphene was withdrawn from the U.S. market in 2010 due to safety concerns, it remains a relevant case study in understanding API sourcing, global supply chains, and regulatory considerations. This article provides a comprehensive analysis of API sources pertinent to DARVOCET A500, emphasizing the complexities of sourcing, manufacturing, and regulation.

Overview of APIs in DARVOCET A500

1. Acetaminophen (Paracetamol)
A widely used analgesic and antipyretic, acetaminophen is characterized by a well-established production network worldwide. It is essential in numerous combination formulations and has a mature supply chain involving multiple regional and global API manufacturers.

2. Propoxyphene Napsylate
An opioid analgesic once common in combination drugs like DARVOCET A500, propoxyphene was removed from the US market due to safety concerns, including cardiotoxicity. Despite regulatory withdrawal, API production persists in certain regions for export or for formulations not yet phased out.

Bulk API Sources for Acetaminophen

Global Manufacturing Network:
Acetaminophen is manufactured by hundreds of suppliers globally, mainly in India, China, and other Asian manufacturing hubs. India is known for its large capacity, economic production, and compliance with international standards.

Major API Producers:

Sun Pharmaceutical Industries (India): One of the world's largest producers of APIs, including acetaminophen, with proven regulatory compliance.
Micro Labs Ltd. (India): Long-standing supplier with a comprehensive product portfolio.
Hubei Westlake University Pharmaceutical (China): Noted for high-volume acetaminophen production.
Mingzhu Pharmaceutical (China): Offers competitive pricing in the Asian API market.

Regulatory and Quality Considerations:
Manufacturers with GMP certification and compliance with FDA, EMA, and other agencies are preferred, ensuring API quality and safety for pharmaceutical applications.

Bulk API Sources for Propoxyphene Napsylate

Regional Variability and Regulatory Status:
Propoxyphene napsylate's production has declined significantly following global regulatory bans; however, some manufacturers continue to produce it mainly for export markets or specialized uses.

Primary Producing Countries:

India: Several unlisted API manufacturers still reportedly produce propoxyphene APIs, albeit at reduced scale.
China: Limited but existing production capacity for propoxyphene, often exported to markets with less stringent regulations.

Key API Suppliers:

Venkatasai Laboratories (India): Historically involved in producing opioids, including propoxyphene.
Sun Pharmaceutical: Reported to produce specific opioids for export, including propoxyphene, although availability may vary due to regulatory restrictions.
Local Chinese manufacturers: Some small-scale producers may still manufacture raw propoxyphene for niche markets.

Regulatory Challenges:
Due to its withdrawal, APIs for propoxyphene are subject to tight controls, and sourcing from licensed and compliant suppliers is crucial to avoid legal and safety issues.

Regulatory Landscape and Impact on API Sourcing

Global Withdrawal of Propoxyphene:
In 2010, FDA issued a black box warning and withdrew DARVOCET A500 and related formulations following studies highlighting serious cardiac risks. Many countries adopted similar measures, leading to decreased production and export of propoxyphene API.

Implications for API Supply Chains:

Reduced availability: Limited current production, primarily in countries with lax regulations.
Risk of counterfeit APIs: Due to high demand in unregulated markets, counterfeit or substandard APIs pose significant risks.
Regulatory restrictions: Importation and use are heavily restricted in markets like the U.S. and EU.

Strategic Sourcing Considerations:

Compliance verification: Ensure API suppliers hold GMP certifications and regulatory approvals.
Traceability: Maintain robust documentation to verify API origin, batch records, and quality standards.
Alternatives: Consider transitioning to non-opioid analgesics due to regulatory constraints surrounding propoxyphene.

Supply Chain and Quality Assurance Strategies

Global API Sourcing Practices:

Engage with well-established suppliers with proven regulatory compliance.
Conduct thorough audits and inspections of manufacturing facilities.
Implement supplier qualification programs emphasizing quality, consistency, and regulatory adherence.

Ensuring API Quality:

Utilize qualified analytical testing methods such as HPLC, GC, and spectroscopic analyses.
Require Certificates of Analysis (CoA) for each batch.
Monitor for potential contamination, impurities, and dosage consistency.

Legal and Ethical Considerations:
Given the legal restrictions, companies sourcing propoxyphene APIs must navigate complex international regulations to prevent legal liabilities and protect patient safety.

Future Outlook and Market Trends

Despite the withdrawal, legacy formulations and ongoing opioid dependence issues across certain regions ensure some demand for propoxyphene APIs. However, increased regulatory scrutiny, development of safer analgesic alternatives, and public health concerns likely suppress long-term API production.

Acetaminophen APIs will continue to enjoy robust demand, supported by the global manufacturing network, diversified supply sources, and consistent regulatory acceptance.

Key Takeaways

Diverse Supply Networks: Acetaminophen boasts a mature, global supply chain with multiple certified producers, ensuring reliable availability.
Regulatory Constraints: The withdrawal of propoxyphene from many markets constrains API sourcing, emphasizing the importance of compliance and due diligence.
Quality and Traceability: High-quality API procurement demands strict quality assurance and supply chain transparency.
Market Outlook: While acetaminophen APIs remain stable, propoxyphene API supply is diminishing, reflecting changing regulatory and safety landscapes.
Strategic Sourcing: Companies should prioritize GMP-compliant, reputable suppliers and consider alternative drugs to avoid regulatory and safety risks associated with obsolete APIs.

FAQs

1. Are API suppliers for propoxyphene napsylate still active globally?
Some suppliers in India and China continue to produce propoxyphene APIs mainly for export to regions with less stringent regulations. However, international concerns and withdrawal from markets like the US drastically limit its global availability.

2. What are the primary regulatory risks associated with sourcing APIs for DARVOCET A500?
The main risks include legal restrictions on opioids, potential for substandard or counterfeit APIs, and compliance-related liabilities. Maintaining GMP certification and regulatory approval documentation is essential.

3. Which regions are the leading sources of acetaminophen APIs?
India and China dominate acetaminophen API production, supported by their extensive manufacturing infrastructure and capacity to meet international quality standards.

4. How does regulatory withdrawal of propoxyphene influence API sourcing strategies?
It pushes companies to seek alternative APIs or formulations, and compels strict due diligence on API suppliers, favoring those with high compliance standards to mitigate legal and safety risks.

5. Can I still obtain propoxyphene APIs for research purposes?
Possibly, but only through licensed suppliers in countries where production is permitted and under strict regulatory oversight. Such procurement requires thorough documentation and adherence to international law.

References

[1] U.S. Food and Drug Administration. (2010). FDA Statutorily Withdraws Approval of Propoxyphene-Containing Products.
[2] European Medicines Agency. (2010). Pharmacovigilance Risk Assessment Committee (PRAC) Recommendations.
[3] Indian Pharmaceutical Association. (2022). API Market Dynamics and Regulatory Environment.
[4] World Health Organization. (2021). Global API Manufacturing and Regulatory Guidance.
[5] MarketWatch. (2021). Trends in Global API Production and Market Share.

Bulk Pharmaceutical API Sources for DARVOCET A500